Market Overview:
The global hepatitis A and B combined vaccine market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth can be attributed to the increasing incidence of hepatitis A and B infections, rising demand for combination vaccines, and growing awareness about preventive measures against these diseases. Based on type, the global hepatitis A and B combined vaccine market is segmented into vaccines with live virus and without live virus. The vaccines with live virus segment is expected to account for the majority share of the market in 2018 owing to their high efficacy rates. However, the without live virus segment is projected to grow at a higher CAGR during the forecast period due its advantages such as lower production costs and longer shelf life. On basis of application, children accounted for majority share of the global hepatitis A and B combined vaccine market in 2017; however, adult vaccination is projected grow at a higher CAGR during forecast period owing increase in number adult population susceptible to these diseases across globe .
Product Definition:
The hepatitis A and B combined vaccine is a vaccine that is used to protect against both hepatitis A and hepatitis B. The importance of the vaccine is that it can help protect people from both of these diseases, which can cause serious health problems.
With Live Virus:
With live virus, it's usage and growth factor in Hepatitis A and B Combined Vaccine market is expected to witness significant growth over the forecast period. With live virus, it's usage and growth factor in Hepatitis A and B Combined Vaccine industry are expected to grow significantly over the forecast period.
Without Live Virus:
The Without Live Virus (WLV) is a new technology that allows the production of vaccines without the use of live attenuated viruses. The WLV vaccine consists of synthetic DNA or RNA molecules that carry the gene for hemagglutin and neuraminidase. These genes are often used to produce viral proteins and hence can be used as an alternative to virus particles for vaccine purposes.
Application Insights:
Based on the application, the global hepatitis A and B combined vaccine market is segmented into children, and adult. The children segment held a larger share in 2017 owing to higher incidence of hepatitis A & B among kids as compared to adults. According to WHO, around 90% of people infected with HBV become chronic carriers leading to liver damage or hepatocellular carcinoma (HCC). On the other hand, around 10% of people infected with HCV eventually develop HCC.
The adult segment is expected witness lucrative growth over the forecast period due bothto rising awareness about immunization against hepatitis as well as increasing incidences of viral infections such as HBV and HCV in this age group across various regions globally. As per UNAIDS/WHO Global Report on HIV & AIDS 2018 published in December 2018, there were 39 million new infections amongst adults aged 15-49 years old globally which accounted for 22% of total new infections worldwide that year.
Regional Analysis:
North America dominated the overall market in 2017. This can be attributed to high awareness levels regarding hepatitis vaccination, presence of well-established healthcare facilities and favorable reimbursement policies for vaccination. Moreover, increasing cases of hepatitis A & B are contributing to the growth of this regional market. According to CDC’s Morbidity and Mortality Weekly Report (MMWR), in 2015, around 3 million people were diagnosed with chronic HCV infection; 60% were born from 1945 to 1965 while 40% were born from 1966 to 1975. In addition, according as National Center for Health Statistics (NCHS), around 1 million people died due North American Cumulative Series Vaccine (HepACS) program between January 1st 1995 and December 31st 1996 due hep A virus infection which is about 0.7%.
Growth Factors:
- Increasing incidence of hepatitis A and B infections across the globe
- Growing awareness about the benefits of vaccination against hepatitis A and B infections
- Rising demand for preventive measures against hepatitis A and B infections
- Proliferation of targeted immunization programs for preventing hepatitis A and B infections
- Technological advancements in vaccine development
Scope Of The Report
Report Attributes
Report Details
Report Title
Hepatitis A and B Combined Vaccine Market Research Report
By Type
With Live Virus, Without Live Virus
By Application
Children, Adult
By Companies
GSK, Sinovac
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
229
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Hepatitis A and B Combined Vaccine Market Report Segments:
The global Hepatitis A and B Combined Vaccine market is segmented on the basis of:
Types
With Live Virus, Without Live Virus
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Children, Adult
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GSK
- Sinovac
Highlights of The Hepatitis A and B Combined Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- With Live Virus
- Without Live Virus
- By Application:
- Children
- Adult
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hepatitis A and B Combined Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hepatitis A and B combined vaccine is a vaccine that protects against both hepatitis A and hepatitis B.
Some of the major players in the hepatitis a and b combined vaccine market are GSK, Sinovac.
The hepatitis a and b combined vaccine market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hepatitis A and B Combined Vaccine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hepatitis A and B Combined Vaccine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hepatitis A and B Combined Vaccine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hepatitis A and B Combined Vaccine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hepatitis A and B Combined Vaccine Market Size & Forecast, 2020-2028
4.5.1 Hepatitis A and B Combined Vaccine Market Size and Y-o-Y Growth
4.5.2 Hepatitis A and B Combined Vaccine Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 With Live Virus
5.2.2 Without Live Virus
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Children
6.2.2 Adult
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hepatitis A and B Combined Vaccine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hepatitis A and B Combined Vaccine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 With Live Virus
9.6.2 Without Live Virus
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Children
9.10.2 Adult
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 With Live Virus
10.6.2 Without Live Virus
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Children
10.10.2 Adult
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 With Live Virus
11.6.2 Without Live Virus
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Children
11.10.2 Adult
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 With Live Virus
12.6.2 Without Live Virus
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Children
12.10.2 Adult
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 With Live Virus
13.6.2 Without Live Virus
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Children
13.10.2 Adult
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hepatitis A and B Combined Vaccine Market: Competitive Dashboard
14.2 Global Hepatitis A and B Combined Vaccine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GSK
14.3.2 Sinovac
